Nasdaq Listing Council stays BCAB delisting, calls review of Feb 6 non-compliance determination

BioAtla, Inc.

Nasdaq determined Feb 6 to delist BCAB for non-compliance with bid price ($1) and stockholders' equity ($2.5M) requirements.
On Feb 8, Nasdaq Listing Council called review of delist decision and stayed suspension; BCAB continues trading on Nasdaq.
Company asserts Nasdaq's delay and policy change on super-voting stock caused irreparable harm.
Listing Council review may take weeks to months; no assurance stock will remain listed after review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.